Tirzepatide Testing: What Happens Before, During and After Treatment

You've been told you might need a blood test before starting, here's what that actually means

This scenario plays out regularly. Someone fills in an online consultation, or visits their GP, and gets told that certain results are needed before treatment can begin. It can feel like a hurdle. In reality, it reflects good clinical practice rather than bureaucracy.

There is no single, universally mandated pre-treatment blood test specified in the tirzepatide SmPC for weight management, but that doesn't mean the prescriber works blind. A thorough assessment covers your BMI, any existing conditions, current medications, kidney and liver health where relevant, and whether tirzepatide is appropriate given your personal history. For people with type 2 diabetes, HbA1c is a standard baseline measure. For others, the prescriber's judgement governs what's checked. You can read how the clinical team at nume approaches these decisions.

One practical thing worth doing before any consultation: pull together whatever recent blood results you have (from a GP check-up or health screening) and have them ready. It takes under a minute to photograph a results letter, and it gives the prescriber more to work with. That small habit can speed up the process considerably.

The tirzepatide blood test question is one our prescribers field most weeks, and the answer is always the same: it depends on your individual picture, not a blanket rule.

Does tirzepatide show up on a drug test?

This is a question that comes up for people in jobs with routine workplace screening, or anyone involved in competitive sport. The direct answer: standard drug-screening panels (whether urine-based, saliva, or hair) are designed to detect controlled substances such as cannabinoids, opioids, amphetamines, benzodiazepines and cocaine. Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is a prescription medicine, not a controlled drug, and it does not appear on these panels.

Specialist panels exist that can detect virtually any compound if the lab is specifically looking for it, but those are not standard occupational health screens. If your employer or sport governing body requires disclosure of prescription medicines, that's a separate obligation under your contract or sport's rules, not a question of whether the standard test picks it up. Our dedicated page on tirzepatide and drug tests covers the evidence in more detail, and the tirzepatide test kit page addresses home-testing scenarios specifically.

For the purposes of MHRA-regulated prescribing and clinical monitoring, this question doesn't change the testing picture at all.

Monitoring during treatment: what to watch for and why it matters

Starting tirzepatide isn't a set-and-forget arrangement. Ongoing monitoring (whether formal or practical) is part of treating responsibly.

Gastrointestinal side effects are the most commonly reported: nausea, loose stools, constipation, reflux and burping tend to cluster around the early weeks and after each dose increase. They're usually transient. Staying hydrated matters more than most people expect, particularly if symptoms are significant, because dehydration can put pressure on kidney function.

In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 class medicines. Severe stomach pain that radiates to the back, with or without vomiting, is a signal to get medical help promptly rather than wait it out. You can report suspected side effects directly at the MHRA's Yellow Card scheme.

People with pre-existing liver or kidney conditions may benefit from periodic bloods during treatment, again, this is a prescriber decision based on your history rather than a universal requirement. Weight loss itself shifts a number of metabolic parameters, which is usually a positive development but worth tracking if you have conditions that interact with those markers.

At nume, every repeat prescription involves a clinical re-review before anything is dispensed. No auto-renewals. The Mounjaro treatment page sets out what that review covers, and our FAQs cover common monitoring questions.

Private treatment, NHS eligibility, and how the assessment differs

Whether you access tirzepatide through the NHS or privately, an assessment happens, the content of that assessment just differs in scope and setting.

NHS eligibility under NICE guidance (TA1026) is specific: BMI thresholds, qualifying comorbidities, and phased rollout cohorts govern who qualifies and when. Privately, the licensed eligibility criteria from the SmPC apply: adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, type 2 diabetes or prediabetes. Lower BMI thresholds can apply for some ethnic backgrounds under NICE's tirzepatide appraisal.

The NHS route involves waiting lists and wraparound support programmes. The private route through a regulated online pharmacy is faster, with no referral needed, though the clinical rigour of the assessment should be equivalent. At nume, that means photo ID verification, live weight confirmation on video, a prescriber reviewing your consultation the same day, and GP notification in line with GPhC guidance. If you'd like to understand your options, our weight-loss overview sets out the full picture.

Cost context is worth knowing: private tirzepatide pricing has shifted substantially since Eli Lilly raised UK list prices in September 2025, with typical private monthly costs now ranging roughly £149 to £375 depending on dose and provider. The Mounjaro cost page explains what that range actually covers and what to check for in any quote.

If the clinical picture is right and you'd like a prescriber to assess your suitability, start your free consultation, it costs nothing and the same-day review means you won't be left waiting.